Paper Details

  1. Home
  2. Paper Details

Prostate cancer screening and treatment: where have we come from and where are we going?

Author: AlbertsenPeter C

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review evaluates the current prostate cancer screening and treatment paradigm based on recently published long-term results from major screening and treatment trials. The review highlights the limitations of prostate-specific antigen (PSA) testing and radical prostatectomy (RP) in identifying and treating clinically significant prostate cancer. The authors propose a shift in screening objectives towards identifying men at higher risk for clinically significant disease and recommend earlier use of antiandrogen therapy to prevent widespread metastases.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate the current prostate cancer screening and treatment paradigm in light of recently published long-term results of major screening and treatment trials. METHODS: Historical review of the evolution of the diagnosis and treatment of prostate cancer followed by a detailed summary ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/bju.15153

データ提供：米国国立医学図書館（NLM）

Prostate Cancer Screening and Treatment: A Complex Landscape

Prostate cancer is a common and often complex health issue. This study takes a deep dive into the current state of prostate cancer screening and treatment, examining the latest research and the ongoing debate surrounding this critical area of medicine.

The authors found that while PSA (prostate-specific antigen) testing can identify prostate cancer early, it often detects low-grade disease that may never pose a significant health threat. This is like finding a faint trail in the vast desert, which may lead to a distant oasis or simply end in a dry wasteland. The challenge lies in distinguishing between the trails that lead to true treasures and those that lead to dead ends.

Refining Prostate Cancer Screening and Treatment Strategies

The study suggests that a more targeted approach to PSA screening is needed, focusing on identifying men at higher risk for aggressive prostate cancer. This would help to reduce unnecessary biopsies and treatments for low-grade disease.

Making Informed Decisions about Prostate Health

Men should discuss prostate cancer screening and treatment options with their doctor. Open communication and shared decision-making are essential for ensuring personalized and effective healthcare.

Dr.Camel's Conclusion

This research navigates the complex and evolving landscape of prostate cancer screening and treatment. Like a camel navigating through the desert, we need to carefully consider the latest research, weigh the potential risks and benefits, and make informed decisions based on individual needs and circumstances.

Date :
  1. Date Completed 2020-12-17
  2. Date Revised 2020-12-17
Further Info :

Pubmed ID

32715604

DOI: Digital Object Identifier

10.1111/bju.15153

Related Literature

Article Analysis
・Effective treatment of prostate cancer screening
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.